8-K Announcements
6Material company update
Mar 16, 2026·SEC
Material company update
Dec 3, 2025·SEC
Material company update
Nov 6, 2025·SEC
Black Diamond Therapeutics, Inc.(BDTX)Earnings, Financials & Key Ratios
BDTX•NASDAQ
$2.82
$161M mkt cap·7.2× P/E·Price updated May 6, 2026
AboutBlack Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA$13M+116.4%
- Net Income$22M+132.1%
- EPS (Diluted)0.39+130.7%
- ROE22.88%+132.8%
- ROIC10.71%+114.0%
- Debt/Equity0.13-49.6%
BDTX Key Insights
Black Diamond Therapeutics, Inc. (BDTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BDTX Price & Volume
Black Diamond Therapeutics, Inc. (BDTX) stock price & volume — 10-year historical chart
Loading chart...
BDTX Growth Metrics
Black Diamond Therapeutics, Inc. (BDTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM129.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM125.71%
Return on Capital
10 Years-39.56%
5 Years-42.83%
3 Years-38.75%
Last Year10.92%
BDTX Recent Earnings
Black Diamond Therapeutics, Inc. (BDTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
Mar 16, 2026EPS
$0.14
Est $0.18
+22.2%
Revenue
—
Est $9M
Q4 2025
Nov 6, 2025EPS
$0.15
Est $0.22
+31.8%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.19
Est $0.25
+24.0%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.98
Est $0.02
+4800.0%
Revenue
$70M
Est $28M
+150.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 16, 2026 | $0.14vs $0.18+22.2% | —vs $9M |
| Q4 2025 | Nov 6, 2025 | $0.15vs $0.22+31.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.19vs $0.25+24.0% | — |
| Q2 2025 | May 12, 2025 | $0.98vs $0.02+4800.0% | $70Mvs $28M+150.0% |
Based on last 12 quarters of dataView full earnings history →
BDTX Peer Comparison
Black Diamond Therapeutics, Inc. (BDTX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 AUPH | 2.15B | 16.25 | 7.85 | 20.38% | 101.47% | 49.4% | 0.13 | |
 ERAS | 3.09B | 10.90 | -15.80 | -36.7% | 0.12 | |||
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 PRME | 615.68M | 3.41 | -2.53 | 55.28% | -43.42% | -178.61% | 0.96 | |
 CGEM | 903.06M | 14.99 | -4.03 | -46.19% | 0.01 |
Compare BDTX vs Peers
Black Diamond Therapeutics, Inc. (BDTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BDTX Income Statement
Black Diamond Therapeutics, Inc. (BDTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70M |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 24K | 44K | 47K | 0 | 0 | 0 | 437K | 0 | 0 | 86K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -24K▲ 0% | -44K▼ 83.3% | -47K▼ 6.8% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -437K▲ 0% | 0▲ 100.0% | 0▲ 0% | 69.91M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | 99.88% |
| Gross Profit Growth % | - | -83.33% | -6.82% | 100% | - | - | - | 100% | - | - |
| Operating Expenses | 4.12M | 8.9M | 29.33M | 69.57M | 126.87M | 92.83M | 86.02M | 78.78M | 57.48M | 58.06M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 666K | 1.95M | 7.58M | 21.36M | 30.04M | 28.39M | 27.11M | 27.47M | 16.57M | 18.58M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 3.45M | 6.95M | 21.75M | 48.21M | 96.83M | 64.44M | 58.91M | 51.31M | 33.56M | 39.56M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -6K | -16K | 0 | 0 | 0 | 0 | 0 | 0 | 7.35M | -86K |
| Operating Income | -4.12M▲ 0% | -8.9M▼ 116.2% | -8.9M▲ 0.0% | -69.57M▼ 681.3% | -126.87M▼ 82.4% | -92.83M▲ 26.8% | -86.46M▲ 6.9% | -78.78M▲ 8.9% | 12.52M▲ 115.9% | 11.86M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | 16.94% |
| Operating Income Growth % | - | -116.17% | 0% | -681.33% | -82.37% | 26.83% | 6.86% | 8.88% | 115.89% | - |
| EBITDA | -4.09M | -8.86M | -8.86M | -68.97M | -126.67M | -92.32M | -86.02M | -78.44M | 12.85M | 12.2M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | 17.43% |
| EBITDA Growth % | - | -116.36% | 0.03% | -678.71% | -83.66% | 27.12% | 6.82% | 8.82% | 116.38% | 115.06% |
| D&A (Non-Cash Add-back) | 24K | 44K | 47K | 600K | 205K | 508K | 437K | 343K | 325K | 344K |
| EBIT | -4.12M | -8.93M | -29.33M | -67.25M | -126.87M | -92.83M | -86.46M | -78.78M | 0 | 17.2M |
| Net Interest Income | 0 | 0 | 461K | 4.04M | 3.46M | 2.03M | 1.92M | 2.18M | 0 | 3.44M |
| Interest Income | 0 | 4K | 461K | 4.04M | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M | 3.44M |
| Interest Expense | 65K | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -483K | -27K | -5.93M | 2.32M | 1.28M | 1.66M | 4.02M | 9.11M | 9.85M | 9.64M |
| Pretax Income | -4.6M▲ 0% | -8.93M▼ 94.1% | -35.26M▼ 294.8% | -67.25M▼ 90.7% | -125.6M▼ 86.7% | -91.17M▲ 27.4% | -82.44M▲ 9.6% | -69.68M▲ 15.5% | 22.37M▲ 132.1% | 21.5M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | 30.71% |
| Income Tax | 0 | -27K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0.3% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.6M▲ 0% | -8.93M▼ 94.1% | -35.26M▼ 294.8% | -67.25M▼ 90.7% | -125.6M▼ 86.7% | -91.17M▲ 27.4% | -82.44M▲ 9.6% | -69.68M▲ 15.5% | 22.37M▲ 132.1% | 21.5M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | 30.71% |
| Net Income Growth % | - | -94.07% | -294.78% | -90.75% | -86.75% | 27.41% | 9.57% | 15.48% | 132.1% | 129.41% |
| Net Income (Continuing) | -4.6M | -8.93M | -35.26M | -67.25M | -125.6M | -91.17M | -82.44M | -69.68M | 22.37M | 21.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.64▲ 0% | -0.64▲ 0.0% | -1.15▼ 79.7% | -2.04▼ 77.4% | -3.47▼ 70.1% | -2.52▲ 27.4% | -1.88▲ 25.4% | -1.27▲ 32.4% | 0.39▲ 130.7% | 0.38▲ 0% |
| EPS Growth % | - | 0% | -79.69% | -77.39% | -70.1% | 27.38% | 25.4% | 32.45% | 130.71% | 125.71% |
| EPS (Basic) | -0.64 | -0.64 | -1.15 | -2.04 | -3.47 | -2.52 | -1.88 | -1.27 | 0.39 | - |
| Diluted Shares Outstanding | 7.2M | 13.95M | 35.91M | 32.91M | 36.19M | 36.23M | 43.95M | 55.03M | 57.56M | 56.93M |
| Basic Shares Outstanding | 7.2M | 13.95M | 35.91M | 32.91M | 36.19M | 36.23M | 43.95M | 55.03M | 56.87M | 56.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BDTX Balance Sheet
Black Diamond Therapeutics, Inc. (BDTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.91M | 51.68M | 155.71M | 319.55M | 215.7M | 127.71M | 134.03M | 101.18M | 132.44M | 138.99M |
| Cash & Short-Term Investments | 7.88M | 51.66M | 154.67M | 315.07M | 209.79M | 122.81M | 131.4M | 98.58M | 20.99M | 135.5M |
| Cash Only | 7.88M | 51.66M | 154.67M | 34.6M | 65.8M | 34.31M | 56.22M | 36.44M | 20.99M | 30.86M |
| Short-Term Investments | 0 | 0 | 0 | 280.46M | 143.99M | 88.49M | 75.18M | 62.14M | 0 | 104.64M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 4.9M | 2.63M | 2.6M | 111.45M | 0 |
| Total Non-Current Assets | 107K | 142K | 2.58M | 10.12M | 31.98M | 28.55M | 24.53M | 21.46M | 10.57M | 18.74M |
| Property, Plant & Equipment | 102K | 134K | 164K | 8.79M | 30.74M | 27.38M | 23.71M | 20.4M | 9.67M | 17.8M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 3.66x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5K | 8K | 2.42M | 1.33M | 1.24M | 1.17M | 823K | 1.07M | 902K | 4.02M |
| Total Assets | 8.02M▲ 0% | 51.83M▲ 546.1% | 158.29M▲ 205.4% | 329.67M▲ 108.3% | 247.68M▼ 24.9% | 156.25M▼ 36.9% | 158.57M▲ 1.5% | 122.64M▼ 22.7% | 143.01M▲ 16.6% | 157.73M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.45x |
| Asset Growth % | - | 546.13% | 205.44% | 108.26% | -24.87% | -36.91% | 1.48% | -22.66% | 16.61% | 26.32% |
| Total Current Liabilities | 2.23M | 2.58M | 4.86M | 14.22M | 23.64M | 15.26M | 19.65M | 20.57M | 15.73M | 15.54M |
| Accounts Payable | 152K | 416K | 1.96M | 2.54M | 4.11M | 1.88M | 2.32M | 4.01M | 579K | 975K |
| Days Payables Outstanding | 2.31K | 3.45K | 15.25K | - | - | - | 1.94K | - | - | 8.89K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.73M | 0 |
| Current Ratio | 3.55x | 20.07x | 32.02x | 22.48x | 9.12x | 8.37x | 6.82x | 4.92x | 8.42x | 8.42x |
| Quick Ratio | 3.55x | 20.07x | 32.02x | 22.48x | 9.12x | 8.37x | 6.82x | 4.92x | 8.42x | 8.42x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 12.47M | 64.79M | 200.59M | 7.69M | 28.14M | 25.3M | 22.18M | 18.78M | 15.07M | 16.04M |
| Long-Term Debt | 0 | 60.77M | 0 | 0 | 0 | 0 | 0 | 0 | 15.07M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 7.69M | 28.14M | 25.3M | 22.18M | 18.78M | 0 | 69.67M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 12.47M | 4.02M | 200.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.7M | 67.37M | 205.45M | 21.91M | 51.78M | 40.56M | 41.83M | 39.35M | 30.8M | 31.58M |
| Total Debt | 12.46M | 60.77M | 0 | 8.74M | 28.46M | 28.14M | 25.3M | 22.19M | 15.07M | 16.04M |
| Net Debt | 4.58M | 9.11M | -154.67M | -25.86M | -37.34M | -6.17M | -30.92M | -14.25M | -5.92M | -14.83M |
| Debt / Equity | - | - | - | 0.03x | 0.15x | 0.24x | 0.22x | 0.27x | 0.13x | 0.13x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 1.17x | 1.31x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.46x | -0.46x |
| Interest Coverage | -63.37x | - | - | -69570.00x | - | - | - | - | - | - |
| Total Equity | -6.67M▲ 0% | -15.54M▼ 132.8% | -47.16M▼ 203.4% | 307.76M▲ 752.6% | 195.9M▼ 36.3% | 115.69M▼ 40.9% | 116.74M▲ 0.9% | 83.28M▼ 28.7% | 112.21M▲ 34.7% | 126.15M▲ 0% |
| Equity Growth % | - | -132.84% | -203.42% | 752.62% | -36.35% | -40.94% | 0.9% | -28.66% | 34.73% | 55.95% |
| Book Value per Share | -0.93 | -1.11 | -1.31 | 9.35 | 5.41 | 3.19 | 2.66 | 1.51 | 1.95 | 2.22 |
| Total Shareholders' Equity | -6.67M | -15.54M | -47.16M | 307.76M | 195.9M | 115.69M | 116.74M | 83.28M | 112.21M | 126.15M |
| Common Stock | 1K | 1K | 1K | 5K | 5K | 5K | 7K | 7K | 8K | 8K |
| Retained Earnings | -6.78M | -15.71M | -50.97M | -118.22M | -243.82M | -334.99M | -417.43M | -487.11M | -464.74M | -449.62M |
| Treasury Stock | 56K | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -56K | -100K | 0 | 614K | -414K | -1.82M | -27K | 24K | 101K | 142K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDTX Cash Flow Statement
Black Diamond Therapeutics, Inc. (BDTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.35M | -8.45M | -24.67M | -52.15M | -100.15M | -85.08M | -66.72M | -62.3M | 29.61M | 29.61M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -259.59% | -191.86% | -111.34% | -92.05% | 15.04% | 21.59% | 6.62% | 147.53% | 412.55% |
| Net Income | -4.6M | -8.93M | -35.26M | -67.25M | -125.6M | -91.17M | -82.44M | -69.68M | 22.37M | 21.5M |
| Depreciation & Amortization | 24K | 44K | 47K | 52K | 205K | 508K | 437K | 343K | 325K | 344K |
| Stock-Based Compensation | 5K | 64K | 3.64M | 7.76M | 14.04M | 12.2M | 9.6M | 10.63M | 6.63M | 5.11M |
| Deferred Taxes | 412K | 0 | 0 | 1.73M | 2.18M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 66K | 15K | 6.43M | 524K | 2.01M | 3.28M | 2M | -905K | 294K | 2.95M |
| Working Capital Changes | 1.74M | 354K | 463K | 5.04M | 7.02M | -9.9M | 3.69M | -2.69M | 0 | -8.56M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -59K | 264K | 1.45M | 1.07M | 1.57M | -2.23M | 597K | 1.68M | -3.43M | -996K |
| Cash from Investing | -77K | -76K | -21K | -281.69M | 130.61M | 53.37M | 16.35M | 16.97M | -44.91M | -14.25M |
| Capital Expenditures | -77K | -76K | -21K | -142K | -2.71M | -192K | -33K | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 118K | 2.7M | 9K | 0 | 94K | 0 | 11K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -118K | -2.7M | 0 | 95K | 0 | 101K | 24K |
| Cash from Financing | 9.97M | 52.31M | 127.76M | 214.94M | 729K | 177K | 71.93M | 25.55M | -146K | 341K |
| Debt Issued (Net) | -50K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 729K | 177K | 1000K | 1000K | 0 | 50K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 10.02M | 0 | -1.74M | 1.1M | 0 | 0 | 82K | 1.05M | -146K | 291K |
| Net Change in Cash | 7.55M▲ 0% | 43.78M▲ 480.2% | 103.06M▲ 135.4% | -118.89M▼ 215.4% | 31.19M▲ 126.2% | -31.54M▼ 201.1% | 21.56M▲ 168.4% | -19.79M▼ 191.8% | -15.44M▲ 22.0% | 7.44M▲ 0% |
| Free Cash Flow | -2.43M▲ 0% | -8.53M▼ 251.3% | -24.7M▼ 189.5% | -52.29M▼ 111.7% | -102.86M▼ 96.7% | -85.27M▲ 17.1% | -66.75M▲ 21.7% | -62.3M▲ 6.7% | 29.61M▲ 147.5% | 21.35M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | 30.49% |
| FCF Growth % | - | -251.32% | -189.51% | -111.74% | -96.71% | 17.1% | 21.72% | 6.66% | 147.53% | 145.93% |
| FCF per Share | -0.34 | -0.61 | -0.69 | -1.59 | -2.84 | -2.35 | -1.52 | -1.13 | 0.51 | 0.51 |
| FCF Conversion (FCF/Net Income) | 0.51x | 0.95x | 0.70x | 0.78x | 0.80x | 0.93x | 0.81x | 0.89x | 1.32x | 0.99x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDTX Key Ratios
Black Diamond Therapeutics, Inc. (BDTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -51.61% | -49.87% | -58.52% | -70.94% | -69.67% | 22.88% | 17.78% |
| Return on Invested Capital (ROIC) | - | - | -130.33% | -43.21% | -51.94% | -66.39% | -76.31% | 10.71% | 10.71% |
| Gross Margin | - | - | - | - | - | - | - | - | 99.88% |
| Net Margin | - | - | - | - | - | - | - | - | 30.71% |
| Debt / Equity | - | - | 0.03x | 0.15x | 0.24x | 0.22x | 0.27x | 0.13x | 0.13x |
| Interest Coverage | - | - | -69570.00x | - | - | - | - | - | - |
| FCF Conversion | 0.95x | 0.70x | 0.78x | 0.80x | 0.93x | 0.81x | 0.89x | 1.32x | 0.99x |
BDTX SEC Filings & Documents
Black Diamond Therapeutics, Inc. (BDTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BDTX Frequently Asked Questions
Black Diamond Therapeutics, Inc. (BDTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in revenue for fiscal year 2025.
Black Diamond Therapeutics, Inc. (BDTX) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Black Diamond Therapeutics, Inc. (BDTX) is profitable, generating $21.5M in net income for fiscal year 2025 (30.7% net margin).
Dividend & Returns
Black Diamond Therapeutics, Inc. (BDTX) has a return on equity (ROE) of 22.9%. This is excellent, indicating efficient use of shareholder capital.
Black Diamond Therapeutics, Inc. (BDTX) generated $21.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More BDTX
Black Diamond Therapeutics, Inc. (BDTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates